Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial

Journal of Diabetes

Volumn 8, Issue 2, 2016, Pages 229-237

  Wang, Weiqing ^a   Yang, Jinkui ^c   Yang, Gangyi ^d   Gong, Yan ^e   Patel, Sanjay ^f   Zhang, Candice ^b   Izumoto, Toshiyasu ^g   Ning, Guang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Boehringer Ingelheim International Trading Co Ltd   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d CHONGQING MEDICAL UNIVERSITY   (China)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f BOEHRINGER INGELHEIM LTD   (United Kingdom)

^g NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

Author keywords

Asian patients; Dipeptidyl peptidase 4 inhibitor; Linagliptin

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLIMEPIRIDE; HEMOGLOBIN A1C; LINAGLIPTIN; METFORMIN; PLACEBO; SULFONYLUREA; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN;

ADD ON THERAPY; ADULT; AGED; ARTICLE; ASIAN; CHINESE; CONTROLLED STUDY; DIABETES CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FILIPINO (PEOPLE); HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALAYSIAN; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; ETHNOLOGY; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; HYPERLIPIDEMIA; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; LINAGLIPTIN; MALE; METFORMIN; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84959105323     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12284     Document Type: Article

References (20)

1. Kang ES, Kim HJ, Ahn CW etal. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res Clin Pract. 2005; 69: 151-159.
2. Kim DJ, Lee MS, Kim KW, Lee MK. Insulin secretory dysfunction and insulin resistance in the pathogenesis of Korean type 2 diabetes mellitus. Metabolism. 2001; 50: 590-593.
3. Ma RC, Chan JC. Type 2 diabetes in East Asians: Similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013; 1281: 64-91.
4. Ko GT, Chan JC, Cockram CS, Woo J. Prediction of hypertension, diabetes, dyslipidaemia or albuminuria using simple anthropometric indexes in Hong Kong Chinese. Int J Obes Relat Metab Disord. 1999; 23: 1136-1142.
5. International Diabetes Federation (IDF). IDF treatment algorithm for people with type 2 diabetes. 2013. Available from: http://www.idf.org/sites/default/files/Type%202%20treatment%20algorithm.pdf (accessed 12 November 2013).
6. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35: 1364-1379.
7. Graefe-Mody U, Retlich S, Friedrich C. Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clin Pharmacokinet. 2012; 51: 411-427.
8. Boehringer Ingelheim Ltd. Trajenta summary of product characteristics. 2012. (updated 19 November 2012). Available from: http://www.medicines.org.uk/emc/medicine/25000/spc (accessed 3 March 2013).
9. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of beta-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab. 2011; 13: 258-267.
10. Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13: 653-661.
11. Taskinen MR, Rosenstock J, Tamminen I etal. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13: 65-74.
12. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: A 24-week randomized study. Diabet Med. 2011; 28: 1352-1361.
13. Zeng Z, Choi DS, Mohan V etal. Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: A pooled analysis. Curr Med Res Opin. 2015; 31: 99-106.
14. Zeng Z, Yang JK, Tong N etal. Efficacy and safety of linagliptin added to metformin and sulphonylurea in Chinese patients with type 2 diabetes: A sub-analysis of data from a randomised clinical trial. Curr Med Res Opin. 2013; 29: 921-929.
15. Gallwitz B, Rosenstock J, Rauch T etal. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: A randomised, double-blind, non-inferiority trial. Lancet. 2012; 380: 475-483.
16. Yang W, Guan Y, Shentu Y etal. The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes. J Diabetes. 2012; 4: 227-237.
17. Pan C, Xing X, Han P etal. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012; 14: 737-744.
18. Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial. Diabetes Res Clin Pract. 2011; 94: 217-224.
19. Laakso M, Rosenstock J, Groop PH etal. Treatment with the dipeptidyl peptidase-4 inhibitor linagliptin or placebo followed by glimepiride in patients with type 2 diabetes with moderate to severe renal impairment: A 52-week, randomized, double-blind clinical trial. Diabetes Care. 2015; 38: e15-e17.
20. McGill JB, Sloan L, Newman J etal. Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: A 1-year, randomized, double-blind, placebo-controlled study. Diabetes Care. 2013; 36: 237-244.